Pharmaceuticals, Biotechnology & Life Sciences

Insider buy: Cable Thomas J. snaps up 7,500 OMEROS shares at $2, buying at a discount amid 107% social‑media buzz—signal of confidence and potential upside.

See why NUVATION BIO’s insider buys signal bullish confidence as safusidenib races toward Phase 3 approval and a potential market rally.

Quart Barry D’s gift sale of 2,600 Kiniksa shares signals insider confidence amid volatile sentiment and rising social‑media buzz.

Inside KURA Onco’s block sale: COO Teresa Brophy sells 31,487 shares at $12.63 under a Rule 10b5‑1 plan—steady divestment, not distress.

Insider sell of 20,626 ACHIEVE Life Sciences shares shows routine liquidity, not a red flag – investors can keep confidence in strong upside and long‑term prospects.

SC US (TTGP) LTD’s disciplined buying of ATYR Pharma’s shares signals long‑term confidence amid a 90% drop, offering investors insight into potential upside if the biotech hits key milestones.

Medpace insider sales rise as CEO Troendle sells 15,609 shares at $606 each—explore what this means for the stock’s future.

Arcutis insider trading shows routine RSU tax moves, not a sell‑off. 1,700 shares sold by CMO Patrick Burnett at $27—no crisis, steady fundamentals and a promising pipeline remain.

REPLIGEN CEO Olivier’s recent 10b5‑1 buy signals confidence in the bioprocessing platform and may boost investor sentiment for future growth.

Insider buying spikes for HUMACYTE show strong confidence despite a 57% YTD drop—discover why directors are piling on shares and what it means for investors.